News

Startup Science: How the Idea for Synthetic Cells Took Silicon Valley By Storm

June 13, 2018
Scientists working on the molecular and cellular level know that big things happen in small systems.

Akili (a UCSF Startup) Digital Medicine Technology Platform Granted Multiple Patents

April 10, 2018
New Patents Issued in U.S. and Japan Broadly Cover Unique Digital Mechanism for Assessing and Improving Cognitive Function Platform Technology Forms Foundation of Digital Medicine in Development to Treat Pediatric Attention-Deficit/Hyperactivity Disorder and Multiple Other Product Candidates

Roche Acquires Inception 5 Multiple Sclerosis (MS) Program Built on Discoveries by Dr. Jonah Chan at UCSF, Versant Forms New Company

April 05, 2018
Building on a four-year-old relationship Roche struck a deal to acquire a regenerative therapy program for multiple sclerosis from Inception Sciences a drug discovery engine co-founded with Versant Ventures in 2011.

Pionyr Immunotherapeutics Completes $62 million Series B Financing to Advance Antibody-Based Therapeutics Targeting the Tumor Microenvironment

December 13, 2017
Two programs directed at myeloid tuning in the tumor microenvironment headed into the clinic

Gilead Sciences and Kite to Acquire Cell Design Labs, One of UCSF Startups for $567 MM

December 07, 2017
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and its cell therapy subsidiary Kite announced that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs, Inc., gaining new technology platforms...

Vium Awards $100K Grant to OncoSynergy, a UCSF Startup to Further Preclinical Research in Ovarian Cancer Model

October 03, 2017
$100K grant will fund study of OncoSynergy’s OS2966 using Vium’s Smart Housing™ Technology

ShangPharma Innovation and UCSF Announce Strategic Research Collaboration

July 13, 2017
A Partnership to Advance Therapies Across the Early-Stage Gap in Biomedical Research In a new collaboration, ShangPharma Innovation, Inc. (SPII) is providing funding and other support to scientists at UC San Francisco (UCSF) to accelerate the development of promising life science inventions.

Infuseon Therapeutics and OncoSynergy Partner to Combat Glioblastoma

June 20, 2017
Infuseon Therapeutics and OncoSynergy have entered into a strategic alliance to test an investigational glioblastoma therapeutic, OS2966, in combination with a novel delivery device, the Cleveland Multiport CatheterTM. Glioblastoma is the most common and malignant primary brain tumor. Despite a...

Pages